PLXPQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLXPQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
PLx Pharma Winddown's Net-Net Working Capital for the quarter that ended in Sep. 2022 was $0.15.
The industry rank for PLx Pharma Winddown's Net-Net Working Capital or its related term are showing as below:
The historical data trend for PLx Pharma Winddown's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLx Pharma Winddown Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Net-Net Working Capital | Get a 7-Day Free Trial | 0.04 | 0.27 | -1.81 | -1.08 | 1.09 |
PLx Pharma Winddown Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Net-Net Working Capital | Get a 7-Day Free Trial | 0.92 | 1.09 | 0.73 | 0.35 | 0.15 |
For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where PLx Pharma Winddown's Price-to-Net-Net-Working-Capital falls into.
PLx Pharma Winddown's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as
Net-Net Working Capital | (A: Dec. 2021 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (69.392 | + | 0.75 * 0.634 | + | 0.5 * 2.458 | - | 24.962 |
- | 16.014 | - | 0) | / | 27.5392 | ||
= | 1.09 |
PLx Pharma Winddown's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2022 is calculated as
Net-Net Working Capital | (Q: Sep. 2022 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (25.834 | + | 0.75 * 0.139 | + | 0.5 * 3.178 | - | 7.023 |
- | 16.014 | - | 0) | / | 29.1377 | ||
= | 0.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
PLx Pharma Winddown (OTCPK:PLXPQ) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of PLx Pharma Winddown's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Rita M O'connor | officer: Chief Financial Officer | 4 OAK PARKWAY, SPARTA NJ 07871 |
Natasha Giordano | director, officer: Chief Executive Officer | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Michael J Valentino | director, officer: Executive Chairman | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
John Hadden | director | 1375 S FORT HARRISON AVE, CLEARWATER FL 33756 |
Robert D. Hardie | 10 percent owner | 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903 |
Molly G. Hardie | 10 percent owner | 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903 |
Level One Partners, Llc | 10 percent owner | 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903 |
Kirk K Calhoun | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Gary S. Balkema | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Robert Casale | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Anthony Bartsh | director | C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939 |
Park West Asset Management Llc | 10 percent owner | 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129 |
Efthymios Deliargyris | officer: Chief Medical Officer | C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054 |
Gary L Mossman | officer: Chief Operating Officer | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
David Emerson Jorden | officer: Acting Chief Financial Officer | 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 03-01-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 01-19-2022
By Marketwired Marketwired • 10-29-2021
By Value_Insider Value_Insider • 10-26-2022
By Don Li2 Don Li2 • 11-01-2021
By GuruFocusNews GuruFocusNews • 05-30-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 04-11-2023
By Marketwired Marketwired • 08-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.